Aurinia Pharmace Stock Price, News & Analysis

Aurinia Pharmaceuticals (NASDAQ: AUPH) will report financial results for the three and nine months ended September 30, 2025 and provide a business update on November 4, 2025.

Management will host a webcast and conference call on November 4, 2025 at 8:30 a.m. ET. The webcast link is available on the company website and a replay will be posted following the event. Dial-in numbers for the call are 877-407-9170 (US) and +1 201-493-6756 (international).

Aurinia (NASDAQ: AUPH) announced five new posters presenting data on LUPKYNIS (voclosporin) at two upcoming meetings: ACR Convergence 2025 in Chicago, IL (October 24–29, 2025) and ASN Kidney Week 2025 in Houston, TX (November 5–9, 2025).

ACR posters cover real‑world effectiveness from the ENLIGHT‑LN registry and pediatric post‑marketing data. ASN posters include mechanistic tissue distribution studies, drug interactions with ketoconazole and rifampin, and ENLIGHT‑LN analyses on concomitant biologic use. Presenters include independent investigators and Aurinia medical lead Ernie Yap, M.D.

The company frames the data as contributing to real‑world and mechanistic understanding of voclosporin in lupus nephritis.

Aurinia Pharmaceuticals (NASDAQ: AUPH) has issued a response to address a retracted LinkedIn post by an FDA official regarding voclosporin. The company firmly stands behind the safety and efficacy profile of LUPKYNIS®, their FDA-approved lupus nephritis treatment.

The company emphasized that LUPKYNIS received full FDA approval in January 2021 based on the AURORA 1 study, and later secured additional approval in April 2024 for long-term use based on the AURORA 2 study, which demonstrated sustained efficacy over three years with comparable safety to AURORA 1.

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported strong Q2 2025 financial results, with total revenue reaching $70.0 million, up 22% year-over-year. LUPKYNIS net product sales increased 21% to $66.6 million in Q2 2025.

The company achieved significant profitability with Q2 net income of $21.5 million and generated $45.5 million in operating cash flow for H1 2025. Aurinia raised its 2025 guidance, now expecting total revenue of $260-270 million and net product sales of $250-260 million.

The Board approved an additional $150 million for share repurchases, following previous buybacks of 18.3 million shares for $138.4 million. The company also reported positive Phase 1 results for aritinercept, planning to initiate clinical studies in multiple autoimmune diseases.

Aurinia Pharmaceuticals (NASDAQ: AUPH) has scheduled the release of its second quarter 2025 financial and operational results before markets open on July 31, 2025. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results.

Investors and interested parties can join the conference call by dialing 877-407-9170 (domestic) or +1 201-493-6756 (international). A replay of the webcast will be made available on Aurinia's website for those unable to attend the live presentation.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced positive results from its Phase 1 single-ascending-dose (SAD) study of aritinercept (AUR200), a dual inhibitor targeting B cell-activating factor (BAFF) and proliferation-inducing ligand (APRIL). The study evaluated six different doses (5mg to 300mg) and placebo in 61 healthy subjects.

The trial demonstrated that aritinercept was well-tolerated across all dose levels, with no treatment-related Grade ≥3 adverse events, serious adverse events, or discontinuations. Key adverse events included injection site reactions (24% aritinercept vs. 13% placebo), headache (11% vs. 7%), and upper respiratory tract infection (7% vs. 0%).

The drug showed significant pharmacodynamic effects, with mean reductions from baseline to Day 28 of up to 48% in immunoglobulin A (IgA), 55% in immunoglobulin M (IgM), and 20% in immunoglobulin G (IgG). Based on these results, Aurinia plans to initiate clinical studies in at least two autoimmune diseases in the second half of 2025.

Aurinia Pharmaceuticals (NASDAQ: AUPH) has scheduled a conference call and webcast for June 30, 2025, at 8:30 a.m. ET to discuss the results of their Phase 1 study for AUR200. The company will provide dial-in options for both domestic (877-407-9170) and international (+1 201-493-6756) participants, with international toll-free access numbers available. A replay of the webcast will be made available on Aurinia's website following the presentation.

Aurinia Pharmaceuticals (NASDAQ: AUPH) presented new post-hoc analysis of its Phase 3 AURORA 1 study at LUPUS 2025, demonstrating superior efficacy of LUPKYNIS-based triple immunosuppressive therapy in lupus nephritis patients. The analysis showed that 60.9% of patients receiving LUPKYNIS with MMF and low-dose glucocorticoids achieved urine protein creatine ratio (UPCR) of ≤0.4 g/g, compared to 37.1% in the control group. Additional analysis revealed distinct lipidomic profiles in patients achieving ultra-low UPCR, suggesting potential cardiovascular benefits. The study found significant improvements in total and LDL cholesterol levels in the LUPKYNIS group. Importantly, adverse event rates remained comparable between treatment groups, supporting LUPKYNIS's safety profile. The findings emphasize LUPKYNIS's crucial role in achieving lower proteinuria targets and improving long-term kidney outcomes for lupus nephritis patients.

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported strong Q1 2025 financial results, with total revenue reaching $62.5 million, up 24% year-over-year. LUPKYNIS, their FDA-approved oral therapy for lupus nephritis, generated net product sales of $60.0 million, a 25% increase from 2024. The company achieved a significant turnaround with net income of $23.3 million, compared to a loss of $10.7 million in Q1 2024. Operating cash flow improved to $1.3 million, versus -$18.6 million last year. Aurinia maintained a strong cash position of $312.9 million and repurchased 5.8 million shares for $47.4 million. The company reaffirmed its 2025 guidance with total revenue of $250-260 million and net product sales of $240-250 million. Additionally, Aurinia expects to report initial results from its Phase 1 study of AUR200 later this quarter.